Viability experiments were performed once. Figure 4 Inhibition of the activity of Kit mutants associated Selleckchem MG 132 with secondary imatinib resistance by motesanib. Autophosphorylation (expressed as a percentage of vehicle control) of wild-type Kit (panel A) and Kit mutants

associated with secondary imatinib resistance (panel B) was assessed in stably transfected Chinese hamster ovary cells treated for 2 hours with single 10-fold serial dilutions of motesanib. Representative data from 1 of 2 experiments are shown. Viability (expressed as the percentage of vehicle control) of Ba/F3 cells expressing the same Kit mutants treated for 24 hours with single 10-fold serial

dilutions of motesanib was also assessed (panel C; not shown: D816V, which had a motesanib IC50 > 3 μM). Viability experiments were performed CBL-0137 datasheet once and representative curves are shown (D816V was not evaluated because Ba/F3 cells expressing this mutant could not be established). Similarly, motesanib inhibited autophosphorylation of the imatinib-resistant activation loop mutant Y823 D (IC50 = 64 nM) more potently than imatinib (IC50 > 3000 nM) (Table 3: Figure 4B). However, neither motesanib nor imatinib inhibited autophosphorylation of the D816V mutant (Table 3). Consistent with these results, motesanib inhibited the growth of Ba/F3 cells transfected with the V560D/V654A, V560D/T670I, or Y823 D mutant more potently than imatinib. Pyruvate dehydrogenase lipoamide kinase isozyme 1 Of note, the IC50 of imatinib against the Y823 D mutant when established in the functional viability assay was at least 10-fold lower than the IC50 measured in the autophosphorylation assay. IL-3-independent Ba/F3 cells expressing the D816V Kit mutant could not be established. Discussion In this study, motesanib was found to be a potent inhibitor

of wild-type Kit, both in vitro and in vivo. In a surrogate marker assay, we observed reversible hair depigmentation in mice treated with motesanib 75 mg/kg twice daily. This dose is comparable to the doses used in xenograft studies demonstrating antitumor and antiangiogenic properties of motesanib [9, 17]. Kit signaling plays an important role in the regulation of hair follicle melanocytes, likely through control of tyrosinase and tyrosinase-related protein 1 (TRP1) expression [16]. Depigmentation has previously been observed in mice treated with anti-Kit antibodies [16, 18] or with sunitinib [18]. Importantly, motesanib had inhibitory activity against Kit mutants associated with GIST and inhibited these mutants more potently than imatinib and generally with an IC50 that was less than or similar to the 24-hour trough concentration of motesanib at therapeutic doses in humans [10].